Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04648293 · ClinicalTrials.gov registry record
Starling Registry Study
A clinical trial, sponsored by Baxter Healthcare Corporation.
- Completed
- Registry status
- 1,207
- Enrollment target
NCT04648293: Completed study, sponsored by Baxter Healthcare Corporation.
NCT04648293 is a clinical trial that has completed, run by Baxter Healthcare Corporation. The registered enrollment target is 1,207 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04648293 has completed, sponsored by Baxter Healthcare Corporation.
- COMPLETED
- Registry status
- 1,207 participants
- Enrollment target
Study Summary
Hemodynamic optimization of critically ill patients is a goal for clinicians in order to afford the patient the best possible outcomes. Being able to precisely and rapidly determine patient fluid responsiveness provides the bedside physician and nursing staff the information needed to make critical decisions in regards to the patient's fluid status and management of additional fluids and medications. As fluid management and cardiac output determination are linked to better decision-making and improved outcomes in ICU, the use of a dynamic assessment of fluid responsiveness becomes a key tool for patient management. This study is designed to collect treatment and outcome data on patients that have undergone hemodynamic monitoring in a wide variety of clinical settings, involving a variety of patient diagnoses.
Interventions
- DEVICE Starling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,207 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2024-02-21 |
What the finished NCT04648293 record still lists
NCT04648293 is an observational study that tracks outcomes without assigning an intervention. Its 1,207 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Starling is the first listed.
NCT04648293 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04648293 about?
NCT04648293 is a clinical study titled "Starling Registry Study". Hemodynamic optimization of critically ill patients is a goal for clinicians in order to afford the patient the best possible outcomes. Being able to precisely and rapidly determine patient fluid responsiveness provides the bedside physician and nursing staff the information needed to make critical ...
What is the current status of trial NCT04648293?
This trial is currently completed. The enrollment target is 1,207 participants. The study started on 2020-11-16. Estimated completion is 2024-02-21.
What interventions are being tested in trial NCT04648293?
The interventions under investigation include: Starling (DEVICE).
Who is sponsoring clinical trial NCT04648293?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946213 · 1,209 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- NCT06535854 · 1,205 participants · NA
Prevail Global Study
- NCT07223593 · 1,205 participants · Phase 3
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
- NCT04267848 · 1,210 participants · Phase 3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI